Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant

This study explores the prognostic value of measurable residual disease (MRD) in multiple myeloma (MM) patients, specifically comparing assessments in peripheral blood (PB) and bone marrow (BM) using next-generation sequencing (NGS). It investigates the effectiveness of early MRD testing after 4 cycles of carfilzomib-based quadruplet induction therapy, highlighting its potential to improve on conventional International Myeloma Working Group (IMWG) response criteria. The findings suggest that integrating both PB and BM MRD assessments could lead to more personalized, risk-adapted treatment strategies for MM patients not undergoing transplant and that early MRD assessment in both compartments provides valuable insights for tailoring treatment intensity and potentially improving outcomes.